8 results

• Rinvoq Warning Label Updated to Add Cancer and Heart Risks Seen With Xeljanz Side Effects

  December 6, 2021

  Irvin Jackson

  Rinvoq will now carry label warnings on cancer and heart risks which were first discovered through a study of Xeljanz side effects.

• Eli Lilly-Funded Study Claims Side Effects of Olumiant Do Not Warrant Same Adverse Label Warnings as Xeljanz

  November 16, 2021

  Irvin Jackson

  A new study announced by Eli Lilly appears to suggest Olumiant, a rheumatoid arthritis drug, does not need the same label warnings for heart problems as Xeljanz, it's competitor.

• Xeljanz Heart Risks May Be Similar Across Other JAK Inhibitors Like Rinvoq, Oluminant: Study

  November 12, 2021

  Irvin Jackson

  A new study suggests the risk of heart problems linked to Xeljanz is similar across all other rheumatoid arthritis drugs belonging to the same class of medications.

• Opzelura Eczema Cream Investigation Announced Over Texture Problems

  November 4, 2021

  Irvin Jackson

  The eczema cream Opzelura, made from the same active ingredient as Jakafi, is being investigated for texture issues as the entire class of drugs faces scrutiny over heart and cancer risks.

• Xeljanz FDA Label Warning Update Adds Information About Risk of Cancer, Blood Clots and Heart Side Effects

  September 2, 2021

  Irvin Jackson

  The FDA is requiring new label warnings for Xeljanz and similar drugs, following a review which revealed links between increased risks of heart attacks, strokes, blood clots, and lymphomas, as well as an increased risk of lung cancer for current or former smokers.

• Experts, FDA Concerned Xeljanz Heart and Cancer Problems May Affect Similar Arthritis Drugs

  July 28, 2021

  Irvin Jackson

  Drugs in the same class as Xeljanz face increased scrutiny over concerns they may carry similar heart and cancer risks such as those suspected of plaguing the arthritis drug.

• FDA Worried Jakafi May Have Cancer, Heart Risks Similar to Xeljanz

  June 10, 2021

  Irvin Jackson

  The FDA has delayed an expanded approval for the drug Jakafi, potentially due to concerns over heart and cancer risks linked to Pfizer's Xeljanz, a similar drug.

• Jakafi Side Effects May Be Linked to PML Brain Disease: Report

  July 12, 2013

  Irvin Jackson

  The bone marrow disease drug Jakafi may be linked to a rare and often deadly brain disease known as PML, according to a U.K. case study.